Author:
Patwardhan Pallavi,Landsteiner Adrienne,Lal Lincy S.,Geevarghese Lincy,Le Lisa,Nandal Savita,Cuker Adam
Abstract
AbstractImmune thrombocytopenia (ITP) may occur in isolation (primary) or in association with a predisposing condition (secondary ITP [sITP]). Eltrombopag is a well-studied treatment for primary ITP, but evidence is scarce for sITP. We evaluated real-world use of eltrombopag for sITP using electronic health records. Eligible patients had diagnoses of ITP and a qualifying predisposing condition, and eltrombopag treatment. We described patient characteristics, treatment patterns, platelet counts, and thrombotic and bleeding events. We identified 242 eligible patients; the most common predisposing conditions were hepatitis C and systemic lupus erythematosus. Average duration of eltrombopag treatment was 6.1 months. Most (81.4%) patients achieved a platelet count ≥ 30,000/µL at a mean of 0.70 months, 70.2% reached ≥ 50,000/µL at a mean of 0.95 months, and 47.1% achieved a complete response of > 100,000/µL at a mean of 1.43 months after eltrombopag initiation. At eltrombopag discontinuation, 105 patients (43%) experienced a treatment-free period for a mean 3.3 months. Bleeding events occurred with similar frequency before and during eltrombopag treatment whereas thrombotic events were less frequent during eltrombopag treatment. Our results suggest similar rates of platelet response with eltrombopag in patients with sITP as compared with primary ITP. In addition, a treatment-free period is possible for a substantial minority of patients.
Funder
Novartis Pharmaceuticals Corporation
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference23 articles.
1. Nugent D, McMillan R, Nichol JL, Slichter SJ (2009) Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol 146(6):585–596. https://doi.org/10.1111/j.1365-2141.2009.07717.x
2. Cines DB, Bussel JB, Liebman HA, Luning Prak ET (2009) The ITP syndrome: pathogenic and clinical diversity. Blood 113:6511–6521. https://doi.org/10.1182/blood-2009-01-129155
3. Cines DB, Liebman H, Stasi R (2009) Pathobiology of secondary immune thrombocytopenia. Semin Hematol 46:S2–S14. https://doi.org/10.1053/j.seminhematol.2008.12.005
4. Arnal C, Piette JC, Léone J, Taillan B, Hachulla E, Roudot-Thoraval F et al (2002) Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 29(1):75–83
5. Kistanguri G, McCrae KR (2013) Immune thrombocytopenia. Hematol Oncol Clin North Am 27(3):495–520. https://doi.org/10.1016/j.hoc.2013.03.001
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献